Colorectal Adenocarcinoma Clinical Trials

16 studies are recruiting for colorectal adenocarcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

   This phase II trial tests the effect of the botensilimab in combination with balstilimab in treating patients with stage II/III colorectal adenocarcinoma with detectable circulating tumor (ct) deoxyribonucleic acid (DNA) in the blood. Immunotherapy with monoclonal antibodies, such as botensilimab a…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ochsner Medical Center Jefferson, New Orleans, Louisiana

   Locations

   2 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07551596 on ClinicalTrials.gov

2. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

   This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical ([225Ac]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   14 in total

   Run by

   Aktis Oncology, Inc.

   See if you can join NCT07020117 on ClinicalTrials.gov

3. A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

   Researchers are looking for a better way to treat people with advanced colorectal cancer. Colorectal cancer (cancer of the colon or rectum) is one of the most common cancers worldwide. Treatments include surgery, chemotherapy, radiotherapy, and immunotherapy; however, these treatments do not work f…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   National Cancer Center Singapore - Oncology Department, Singapore,

   Locations

   122 in total

   Run by

   Vividion Therapeutics, Inc.

   See if you can join NCT07811193 on ClinicalTrials.gov

4. Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

   This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

   Stage

   Phase 1

   Ages

   12 to 85

   Site

   Precision NextGen Oncology and Research, Beverly Hills, California

   Locations

   37 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT03715933 on ClinicalTrials.gov

5. Family Communications After Genetic Testing

   This clinical trial compares patient (proband)-mediated communication to provider-mediated communication for improving genetic testing in first-degree relatives of patients with newly diagnosed colorectal cancer. It is estimated that 30% of cases of colorectal cancer have a genetic basis and about …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Anchorage Associates in Radiation Medicine, Anchorage, Alaska

   Locations

   319 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT07143487 on ClinicalTrials.gov

6. Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)

   This is a phase II open-label, basket clinical trial to assess the feasibility of systemic and Intraperitoneal chemotherapy in subjects with Gastrointestinal Malignancies with Peritoneal Carcinomatosis. These are subjects who have a proven primary carcinoma of the digestive tract..

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT07795749 on ClinicalTrials.gov

7. TLR9 Immunotherapy for Peritoneal Carcinomatosis

   The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites. The main questions it aims to answer are: • To determine the safety and maximum tolerated dose (MTD) or optimal biologic dose (OBD) of intraperitoneal inj…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Rhode Island and the Miriam Hospitals (Brown University Health), Providence, Rhode Island

   Run by

   Brown University

   See if you can join NCT07658196 on ClinicalTrials.gov

8. Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer

   This phase I trial tests whether fluoxetine (prozac) works to modify the tumor immune cells before surgery in patients with colorectal cancer. Fluoxetine is a commonly used selective serotonin reuptake inhibitor (SSRI) prescribed for major depressive disorder and generalized anxiety. Giving fluoxet…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT06225011 on ClinicalTrials.gov

9. A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis

   This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).

   Stage

   Not phased

   Ages

   18 to 81

   Site

   Yale New Haven Hospital, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT07291180 on ClinicalTrials.gov

10. Stage II/III Colorectal Cancer Recurrence

    This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.

    Stage

    Not phased

    Ages

    18 and older

    Site

    City of Hope Medical Center, Monrovia, California

    Locations

    4 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06314958 on ClinicalTrials.gov

11. Early Onset Colorectal Cancer Detection

    Colorectal cancer (CRC) once predominantly affected older individuals, but in recent years has witnessed a progressive increase in incidence among young adults. Once rare, early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now constitutes 10-15% of all newly diagno…

    Stage

    Not phased

    Ages

    18 to 50

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    13 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06342401 on ClinicalTrials.gov

12. Early Detection of Advanced Adenomas and Colorectal Cancer

    This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.

    Stage

    Not phased

    Ages

    18 and older

    Site

    City of Hope Medical Center, Monrovia, California

    Locations

    6 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06342440 on ClinicalTrials.gov

13. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

    The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner Health, Gilbert, Arizona

    Locations

    12 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06051695 on ClinicalTrials.gov

14. Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

    This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied furt…

    Stage

    Not phased

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Locations

    10 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT04739072 on ClinicalTrials.gov

15. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    21 in total

    Run by

    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

16. A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

    The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    10 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06682793 on ClinicalTrials.gov